GB201803563D0 - Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases - Google Patents

Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases

Info

Publication number
GB201803563D0
GB201803563D0 GBGB1803563.4A GB201803563A GB201803563D0 GB 201803563 D0 GB201803563 D0 GB 201803563D0 GB 201803563 A GB201803563 A GB 201803563A GB 201803563 D0 GB201803563 D0 GB 201803563D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
treatment
pharmaceutical compositions
skin diseases
autoimmune skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1803563.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Morphosys AG
Original Assignee
Galapagos NV
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV, Morphosys AG filed Critical Galapagos NV
Priority to GBGB1803563.4A priority Critical patent/GB201803563D0/en
Publication of GB201803563D0 publication Critical patent/GB201803563D0/en
Priority to PCT/IB2019/051761 priority patent/WO2019171267A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
GBGB1803563.4A 2018-03-06 2018-03-06 Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases Ceased GB201803563D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1803563.4A GB201803563D0 (en) 2018-03-06 2018-03-06 Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
PCT/IB2019/051761 WO2019171267A1 (en) 2018-03-06 2019-03-05 Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1803563.4A GB201803563D0 (en) 2018-03-06 2018-03-06 Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases

Publications (1)

Publication Number Publication Date
GB201803563D0 true GB201803563D0 (en) 2018-04-18

Family

ID=61903635

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1803563.4A Ceased GB201803563D0 (en) 2018-03-06 2018-03-06 Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases

Country Status (2)

Country Link
GB (1) GB201803563D0 (en)
WO (1) WO2019171267A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69839147T2 (en) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. ARTIFICIAL ANTIBODY POLYPEPTIDE
PT1076703E (en) 1998-05-15 2007-10-10 Genentech Inc Therapeutic uses of il-17 homologous polypeptides
US20120201821A1 (en) * 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
SG11201401202YA (en) 2011-10-19 2014-06-27 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
WO2016096896A1 (en) * 2014-12-15 2016-06-23 Morphosys Ag Antibodies for il-17c
CN108135913A (en) 2015-10-05 2018-06-08 莫佛塞斯公司 Treatment and/or the IL-17C antagonists of prevention atopic dermatitis
SG11201806161TA (en) 2016-02-19 2018-08-30 Morphosys Ag Antibodies for il-17c
US20230203149A1 (en) * 2017-09-25 2023-06-29 Morphosys Ag Treatment of atopic dermatitis

Also Published As

Publication number Publication date
WO2019171267A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3471735A4 (en) Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
EP3506926A4 (en) Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases
EP4009948A4 (en) Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders
IL279397A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL274578A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
IL288375A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
IL286343A (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
IL286767A (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3740592A4 (en) Methods and compositions for the treatment of vascular disease
PL3515409T3 (en) Complex and compositions for the treatment of ophthalmic and dermatological diseases
IL285751A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL272495A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201803563D0 (en) Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
EP3846843A4 (en) Compositions and methods for the treatment of heart disease
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
GB201809836D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3682891A4 (en) Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)